PARP inhibitors
Amoy Diagnostics, AstraZeneca Partner to Advance PARP Inhibitor CDx For Maintenance Indication
AmoyDx's test, if approved, would identify patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are eligible for maintenance treatment.
Thermo Fisher Introduces Homologous Recombination Deficiency Score for Cancer Profiling Assay
Premium
The firm is also bringing its comprehensive genomic profiling assay for cancer to the Ion Torrent Genexus sequencing platform in the first half of 2023.
Myriad Genetics Gets Expanded Coverage for BRACAnalysis CDx in Japan
Testing will be reimbursed for patients with early-stage breast cancer to guide adjuvant treatment with the PARP inhibitor Lynparza.
Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response
The collaboration between Mass General and Switzerland's Lunaphore will initially focus on developing a test for ovarian, breast, and prostate cancers.
Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development
The companies will cooperate in drug target discovery and, potentially, companion diagnostic development for novel synthetic lethal inhibitors.